Eyevensys has received an equity investment by the Boehringer Ingelheim Venture Fund (BIVF). Eyevensys is a developer of a new process for non-viral gene therapy using electrotransfer that enables prolonged production of therapeutic proteins for the treatment of ocular disease. Additionally, Dr. Michel Pairet, Boehringer’s head of non-clinical R&D, has been appointed to the company’s board of directors.
   This equity investment initiates Eyevensys’ next round of funding, which a...